Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,041 to 2,060 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Placebo Bid + Symbicort 'as Needed' (Experimental) vs Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator): deaths from any cause | 1 of 2,089 1 of 2,087 | -0.0 points -0.2 to 0.2 | 4,176 | NCT02224157 A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma |
| Placebo Bid + Symbicort 'as Needed' (Experimental) vs Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator): Number of Participants With Study Specific Asthma Related Discontinuation | 0 of 2,089 4 of 2,087 | -0.2 points -0.5 to 0.0 | 4,176 | NCT02224157 A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma |
| Placebo Bid + Symbicort 'as Needed' (Experimental) vs Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator): Number of Participants Experiencing at Least One Severe Asthma Exacerbation | 177 of 2,089 184 of 2,087 | -0.3 points -2.1 to 1.4 | 4,176 | NCT02224157 A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma |
| Placebo Bid + Symbicort 'as Needed' (Experimental) vs Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator): serious adverse events | 66 of 2,089 73 of 2,087 | -0.3 points -1.4 to 0.8 | 4,176 | NCT02224157 A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma |
| Colchicine vs Placebo: Number of Participants Who Died or Were Hospitalized Due to COVID-19 Infection in the 30 Days Following Randomization in the Subgroup of Patients With PCR-confirmed COVID-19. | 96 of 2,075 126 of 2,084 | -1.4 points -2.8 to -0.1 | 4,159 | NCT04322682 Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) |
| Receives OUD-CDS vs Does Not Receive the OUD-CDS: Number of Patients With OUD Diagnosis | 36 of 2,079 24 of 2,074 | 0.6 points -0.2 to 1.3 | 4,153 | NCT04198428 Clinical Decision Support for Opioid Use Disorders in Medical Settings (COMPUTE 2.0) |
| All TNFi Initiators Combination vs Tofacitinib Initiators Monotherapy: Number of Participants With mACR20 at 6 Months for Tofacitinib Monotherapy vs TNFi Combination With MTX | 1,224 of 4,013 28 of 135 | 9.8 points 2.0 to 15.9 | 4,148 | NCT05576051 To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting. |
| IRBESARTAN vs PLACEBO: serious adverse events | 1,146 of 2,064 1,155 of 2,062 | -0.5 points -3.5 to 2.5 | 4,126 | NCT00095238 Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve) |
| Ivermectin Mass Drug Administration vs Placebo Mass Administration: deaths from any cause | 6 of 2,191 3 of 1,933 | 0.1 points -0.2 to 0.5 | 4,124 | NCT03967054 Repeat Ivermectin Mass Drug Administrations for MALaria Control II |
| Ivermectin Mass Drug Administration vs Placebo Mass Administration: serious adverse events | 8 of 2,191 6 of 1,933 | 0.1 points -0.4 to 0.4 | 4,124 | NCT03967054 Repeat Ivermectin Mass Drug Administrations for MALaria Control II |
| BCG-vaccine vs Control Children: DTaP-IPV-Hib Vaccination Coverage at 12 Months of Age | 1,175 of 2,018 1,207 of 2,097 | 0.7 points -2.3 to 3.7 | 4,115 | NCT01694108 Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children. |
| VLA1553 vs Placebo: Serious Adverse Event | 46 of 3,082 8 of 1,033 | 0.7 points -0.1 to 1.3 | 4,115 | NCT04546724 Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults |
| VLA1553 vs Placebo: Related Adverse Event of Special Interest | 9 of 3,082 1 of 1,033 | 0.2 points -0.3 to 0.5 | 4,115 | NCT04546724 Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults |
| VLA1553 vs Placebo: Related Serious Adverse Event | 2 of 3,082 0 of 1,033 | 0.1 points -0.3 to 0.2 | 4,115 | NCT04546724 Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults |
| VLA1553 vs Placebo: Unsolicited AEs | 687 of 3,082 138 of 1,033 | 8.9 points 6.3 to 11.4 | 4,115 | NCT04546724 Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults |
| VLA1553 vs Placebo: Related Adverse Events | 1,575 of 3,082 322 of 1,033 | 19.9 points 16.5 to 23.2 | 4,115 | NCT04546724 Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults |
| VLA1553 vs Placebo: Adverse Event of Special Interest | 10 of 3,082 1 of 1,033 | 0.2 points -0.2 to 0.5 | 4,115 | NCT04546724 Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults |
| VLA1553 vs Placebo: deaths from any cause | 2 of 3,082 1 of 1,033 | -0.0 points -0.5 to 0.2 | 4,115 | NCT04546724 Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults |
| VLA1553 vs Placebo: serious adverse events | 46 of 3,082 8 of 1,033 | 0.7 points -0.1 to 1.3 | 4,115 | NCT04546724 Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults |
| rIL-2 vs No rIL-2: Grade 4 Signs and Symptoms | 466 of 2,071 383 of 2,040 | 3.7 points 1.3 to 6.2 | 4,111 | NCT00004978 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy |
Code
curl "https://conductscience.org/api/comparisons/v1?page=103"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=103
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02224157-deaths",
"title": "Placebo Bid + Symbicort 'as Needed' (Experimental) vs Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator): deaths from any cause",
"summary": "1 of 2089 against 1 of 2087; risk difference -0.0 points, 95% interval -0.2 to 0.2; NCT02224157, A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma",
"record": "/library/comparisons/NCT02224157-deaths",
"nct_id": "NCT02224157",
"kind": "deaths",
"participants": 4176,
"risk_difference": {
"value": -4.5874263689398443e-7,
"lower": -0.0022651163914397896,
"upper": 0.0022621671366750942
},
"group_1": "1 of 2,089",
"group_2": "1 of 2,087",
"difference": "-0.0 points",
"interval": "-0.2 to 0.2",
"trial_title": "A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma"
},
{
"id": "NCT02224157-f8ac8bc7",
"title": "Placebo Bid + Symbicort 'as Needed' (Experimental) vs Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator): Number of Participants With Study Specific Asthma Related Discontinuation",
"summary": "0 of 2089 against 4 of 2087; risk difference -0.2 points, 95% interval -0.5 to 0.0; NCT02224157, A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma",
"record": "/library/comparisons/NCT02224157-f8ac8bc7",
"nct_id": "NCT02224157",
"kind": "outcome",
"participants": 4176,
"risk_difference": {
"value": -0.0019166267369429804,
"lower": -0.00491790626171383,
"upper": 0.00026063936880732844
},
"group_1": "0 of 2,089",
"group_2": "4 of 2,087",
"difference": "-0.2 points",
"interval": "-0.5 to 0.0",
"trial_title": "A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=104",
"request_id": "v5qRvCrTxZggv7BH"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant